



MEN

FIRST CANCER SITE
SOFT TISSUESOFT TISSUE
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

TESSUTI MOLLI
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	3994		4303		4303		3994		3106		1374		584		3994	4303
Person-years ▶	18554		19244		691		2928		8184		4569		2872		18554	19244
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND SOFT TISSUE	258	1.05	278	1.09	20	2.10	49	1.28	106	1.01	61	1.01	42	0.98	0.62	1.14
HEAD AND NECK	14	1.31	15	1.35	1	2.40	4	2.35	6	1.29	4	1.53	0	0.00	0.18	0.20
ORAL CAVITY	3	1.17	3	1.12	0	0.00	1	2.49	2	1.80	0	0.00	0	0.00	0.02	0.02
PHARYNX	2	0.85	2	0.82	0	0.00	1	2.71	0	0.00	1	1.73	0	0.00	-0.02	-0.02
LARYNX	9	1.57	10	1.68	1	4.36	2	2.15	4	1.60	3	2.15	0	0.00	0.18	0.21
OESOPHAGUS	0	0.00	1	0.36	1	9.60	0	0.00	0	0.00	0	0.00	0	0.00	-0.14	-0.09
STOMACH	11	0.74	12	0.77	1	1.63	2	0.82	6	0.93	3	0.83	0	0.00	-0.21	-0.18
COLON RECTUM	41	1.22	43	1.23	2	1.55	9	1.74	16	1.13	10	1.21	6	1.02	0.40	0.42
COLON	25	1.09	27	1.13	2	2.28	4	1.14	13	1.34	5	0.88	3	0.74	0.11	0.17
RECTUM	16	1.50	16	1.45	0	0.00	5	3.00	3	0.66	5	1.91	3	1.65	0.29	0.26
LIVER	6	0.61	6	0.59	0	0.00	2	1.31	1	0.24	1	0.42	2	1.19	-0.20	-0.22
GALLBLADDER	2	0.77	2	0.74	0	0.00	0	0.00	0	0.00	1	1.56	1	2.25	-0.03	-0.04
PANCREAS	3	0.45	3	0.43	0	0.00	1	0.97	1	0.35	1	0.60	0	0.00	-0.20	-0.20
LUNG	30	0.71	33	0.75	3	1.79	6	0.89	15	0.83	3	0.29	6	0.86	-0.65	-0.56
SKIN MELANOMA	3	0.76	3	0.74	0	0.00	0	0.00	2	1.21	0	0.00	1	1.40	-0.05	-0.06
MESOTHELIOMA	3	2.35	3	2.27	0	0.00	1	5.26	2	3.74	0	0.00	0	0.00	0.09	0.09
KAPOSI SARCOMA	3	5.12	3	4.93	0	0.00	1	10.67	0	0.00	1	7.05	1	10.33	0.13	0.12
SOFT TISSUE	1	1.04	1	1.00	0	0.00	0	0.00	0	0.00	0	0.00	1	6.15	0.00	0.00
BONE	3	10.93	3	10.52	0	0.00	0	0.00	2	16.76	0	0.00	1	22.59	0.15	0.14
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
PROSTATE	61	1.31	65	1.34	4	2.31	8	1.15	27	1.40	21	1.82	5	0.57	0.77	0.86
TESTIS	0	0.00	1	1.26	1	37.85	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	0.01
KIDNEY AND RENAL PELVIS	9	1.15	12	1.48	3	10.28	0	0.00	3	0.90	2	1.03	4	2.91	0.06	0.20
BLADDER AND URINARY TRACT	27	1.00	29	1.03	2	1.88	4	0.94	8	0.69	8	1.20	7	1.51	-0.01	0.04
URINARY BLADDER	27	1.04	29	1.08	2	1.96	4	0.98	8	0.72	8	1.26	7	1.58	0.06	0.11
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.06	-0.06
BRAIN AND CENTRAL NERVOUS SYSTEM	3	0.98	3	0.94	0	0.00	0	0.00	0	0.00	1	1.34	2	3.93	0.00	-0.01
THYROID	4	2.84	4	2.75	0	0.00	1	4.85	0	0.00	1	2.83	2	8.07	0.14	0.13
HODGKIN LYMPHOMA	1	1.38	1	1.33	0	0.00	0	0.00	1	3.14	0	0.00	0	0.00	0.01	0.01
NON-HODGKIN LYMPHOMA	3	0.41	3	0.39	0	0.00	1	0.89	1	0.32	0	0.00	1	0.79	-0.23	-0.24
MYELOMA	3	0.92	3	0.89	0	0.00	0	0.00	1	0.72	0	0.00	2	3.57	-0.01	-0.02
LEUKAEMIAS	8	1.37	10	1.65	2	8.57	4	4.30	3	1.20	0	0.00	1	1.03	0.12	0.20
LYMPHOID LEUKAEMIAS	3	1.07	5	1.71	2	17.77	2	4.45	1	0.83	0	0.00	0	0.00	0.01	0.11
MYELOID LEUKAEMIAS	5	1.92	5	1.85	0	0.00	2	4.86	2	1.80	0	0.00	1	2.26	0.13	0.12
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	20	1.54	20	1.48	0	0.00	5	2.45	11	1.99	4	1.25	0	0.00	0.38	0.34

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN FIRST CANCER SITE SOFT TISSUE

SOFT TISSUE POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

TESSUTI MOLLI POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	3458		3714		3714		3458		2711		1213		560		3458	3714
Person-years ▶	16709		17306		597		2540		7199		4250		2720		16709	17306
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND SOFT TISSUE	159	1.13	170	1.17	11	2.17	28	1.35	67	1.16	37	1.01	27	1.04	1.09	1.40
HEAD AND NECK	1	0.55	1	0.53	0	0.00	0	0.00	1	1.34	0	0.00	0	0.00	-0.05	-0.05
ORAL CAVITY	1	1.05	1	1.01	0	0.00	0	0.00	1	2.59	0	0.00	0	0.00	0.00	0.00
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OESOPHAGUS	1	1.54	1	1.48	0	0.00	1	10.26	0	0.00	0	0.00	0	0.00	0.02	0.02
STOMACH	8	1.03	8	0.99	0	0.00	1	0.82	3	0.94	1	0.50	3	2.15	0.01	-0.01
COLON RECTUM	20	0.96	20	0.93	0	0.00	1	0.33	9	1.07	2	0.37	8	2.05	-0.05	-0.09
COLON	14	0.94	14	0.90	0	0.00	0	0.00	7	1.17	1	0.26	6	2.12	-0.06	-0.09
RECTUM	6	1.02	6	0.98	0	0.00	1	1.13	2	0.83	1	0.65	2	1.85	0.01	-0.01
LIVER	1	0.29	1	0.28	0	0.00	0	0.00	0	0.00	0	0.00	1	1.54	-0.15	-0.15
GALLBLADDER	1	0.36	1	0.35	0	0.00	0	0.00	0	0.00	0	0.00	1	1.96	-0.11	-0.11
PANCREAS	2	0.38	2	0.36	0	0.00	0	0.00	1	0.48	1	0.72	0	0.00	-0.20	-0.20
LUNG	17	1.97	18	2.02	1	3.32	3	2.43	6	1.73	7	3.10	1	0.60	0.50	0.52
SKIN MELANOMA	4	1.38	7	2.33	3	30.51	3	7.24	0	0.00	0	0.00	1	1.86	0.07	0.23
MESOTHELIOMA	1	2.74	1	2.65	0	0.00	0	0.00	1	6.85	0	0.00	0	0.00	0.04	0.04
KAPOSI SARCOMA	0	0.00	1	5.47	1	145.14	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	0.05
SOFT TISSUE	1	1.61	1	1.55	0	0.00	1	10.67	0	0.00	0	0.00	0	0.00	0.02	0.02
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	50	1.32	53	1.36	3	2.28	11	2.01	17	1.09	16	1.63	6	0.88	0.73	0.80
CERVIX UTERI	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.13	-0.13
CORPUS UTERI	7	1.07	8	1.18	1	4.32	1	1.04	3	1.10	3	1.77	0	0.00	0.03	0.07
OVARY	5	1.11	5	1.07	0	0.00	1	1.48	2	1.06	0	0.00	2	2.50	0.03	0.02
KIDNEY AND RENAL PELVIS	7	2.11	7	2.04	0	0.00	1	2.09	1	0.74	3	3.45	2	3.17	0.22	0.21
BLADDER AND URINARY TRACT	5	0.99	5	0.95	0	0.00	0	0.00	5	2.46	0	0.00	0	0.00	0.00	-0.01
URINARY BLADDER	4	0.85	4	0.82	0	0.00	0	0.00	4	2.11	0	0.00	0	0.00	-0.04	-0.05
URINARY TRACT	1	2.82	1	2.72	0	0.00	0	0.00	1	7.13	0	0.00	0	0.00	0.04	0.04
BRAIN AND CENTRAL NERVOUS SYSTEM	1	0.48	2	0.93	1	13.46	0	0.00	1	1.16	0	0.00	0	0.00	-0.06	-0.01
THYROID	5	1.57	6	1.83	1	9.78	1	2.26	2	1.51	1	1.20	1	1.73	0.11	0.16
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	7	1.34	7	1.30	0	0.00	0	0.00	6	2.82	1	0.74	0	0.00	0.11	0.09
MYELOMA	4	1.72	4	1.66	0	0.00	0	0.00	4	4.23	0	0.00	0	0.00	0.10	0.09
LEUKAEMIAS	5	1.47	5	1.42	0	0.00	1	1.95	2	1.44	2	2.28	0	0.00	0.10	0.09
LYMPHOID LEUKAEMIAS	2	1.34	2	1.29	0	0.00	0	0.00	1	1.63	1	2.61	0	0.00	0.03	0.03
MYELOID LEUKAEMIAS	3	1.84	3	1.78	0	0.00	1	4.15	1	1.51	1	2.36	0	0.00	0.08	0.08
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OTHER AND ILL DEFINED SITES	7	0.61	7	0.59	0	0.00	3	1.36	3	0.76	0	0.00	1	0.53	-0.23	-0.24

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio